What are the Challenges in Developing miRNA Inhibitors?
Despite their potential, several challenges hinder the development of miRNA inhibitors:
Delivery: Efficient and targeted delivery of miRNA inhibitors to the specific cancer cells remains a significant challenge. Nanoparticle-based delivery systems and conjugation with cell-penetrating peptides are being explored to overcome this hurdle. Stability: miRNA inhibitors need to be stable in the bloodstream and within cells to exert their effect. Chemical modifications, such as LNAs, enhance the stability and binding affinity of these inhibitors. Off-target Effects: miRNA inhibitors might bind to unintended targets, leading to off-target effects. Specificity is crucial to minimize these adverse effects and improve therapeutic outcomes.
